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Objectives This study sought to compare the association of microalbuminuria with outcomes in patients with different
comorbidities.
Background The risk of adverse outcomes associated with lower levels proteinuria has been found to be linearly decreasing with even
low-normal levels of microalbuminuria. It is unclear whether comorbid conditions change these associations.
Methods We examined the association of urine microalbumin-creatinine ratio (UACR) with mortality and the slopes of es-
timated glomerular filtration rate (eGFR) in a nationally representative cohort of 298,875 U.S. veterans. Associa-
tions of UACR with all-cause mortality overall and in subgroups of patients with and without diabetes mellitus,
hypertension, cardiovascular disease, congestive heart failure, and advanced chronic kidney disease (CKD) were
examined in Cox models, and with the slopes of eGFR in linear and logistic regression models.
Results Very low levels of UACR were linearly associated with decreased mortality and less progression of CKD overall:
adjusted mortality hazard ratio and estimated glomerular filtration rate slope (95% confidence interval [CI]) as-
sociated with UACR 200 g/mg, compared to 5 g/mg were 1.53 (95% CI: 1.38 to 1.69, p  0.001) and
1.59 (95% CI: 1.83 to 1.35, p  0.001). Similar linearity was present in all examined subgroups, except in
patients with CKD in whom a U-shaped association was present and in whom a UACR of 10 to 19 was associated
with the best outcomes.
Conclusions The association of UACR with mortality and with progressive CKD is modified in patients with CKD, who experi-
ence higher mortality and worse progression of CKD with the lowest levels of UACR. Proteinuria-lowering inter-
ventions in patients with advanced CKD should be implemented cautiously, considering the potential for adverse
outcomes. (J Am Coll Cardiol 2013;61:1626–33) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.071The high burden of cardiovascular disease in the general
population (1) has prompted enhanced efforts to identify
early disease markers and therapeutic targets. Microalbu-
minuria has shown associations with morbidity and mortal-
ity in the general population (2–7), and in patients with
various comorbid conditions such as those at risk for or with
established chronic kidney disease (CKD) (8–13). An impor-
tant question about microalbuminuria is the level that should
be applied as a cutoff both toward identifying increased
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commonly used classification for the levels of urine
microalbumin-creatinine ratio (UACR [the test most readily
available in clinical practice]) defines a level of 10 g/mg as the
See page 1634
upper limit of normal (15 g/mg for females, to account
for the higher urine creatinine of males) (14). Neverthe-
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April 16, 2013:1626–33 Outcomes Associated With Microalbuminurialess, studies in the general population have suggested that
even UACR levels 10 g/mg are associated with a
inear decrement in event risks (3,6,15) questioning the
dea of an “ideal” or “normal” range for this marker, and
mplying that a “the lower, the better” approach is warranted
or risk stratification, and potentially for therapeutic
nterventions.
It is unclear to what extent these findings, and hence this
oncept, can be applied to patients with a high burden of
omorbidities, whose risk of adverse outcomes such as
ortality, cardiovascular events, and progressive kidney
isease is substantially higher. Studies that examined pa-
ients with established CKD have, in general, found that
ower UACR was associated with decreased incidence of
ortality and end-stage renal disease (8–13), but neither
he individual studies nor the meta-analyses pooling their
esults (8,10) performed a detailed analysis of UACR cutoffs
elow what is currently considered “normal” in this patient
opulation. We examined the association of UACR with
ortality and with progressive CKD in a large cohort of
.S. veterans. We studied UACR ranges that included even
hose below the currently accepted normal level of 10
g/mg, and explored whether the associations differed in
patients with and without diabetes mellitus, cardiovascular
disease (CVD), congestive heart failure (CHF), CKD, and
in those with higher and lower levels of blood pressure.
Methods
Cohort definition. The establishment of our cohort was
described previously (16). Briefly, we extracted all the available
measurements of UACR and stable estimated glomerular
filtration rate (eGFR) from the period between October 1,
2004, and September 30, 2006, from the Veterans Adminis-
tration (VA) Decision Support System National Data Extracts
Laboratory Results file (a VA-wide database containing select
laboratory results obtained in the clinical setting) (17). The
GFR was estimated from serum creatinine measurements and
demographic characteristics by the Chronic Kidney Disease
Epidemiology Collaboration equation (18). Of a total of
4,381,049 patients with any serum creatinine and 438,503
patients with any UACR measured between October 1, 2004
and September 30, 2006, we identified 298,875 patients with
both stable kidney function and available UACR.
Sociodemographic characteristics and comorbidities.
Data on patient age, sex, race, geographic location (Veteran
Integrated Service Network number), blood pressure, and
administration of angiotensin-converting enzyme inhibitor
(ACEI) or angiotensin-receptor blocker (ARB) was ob-
tained through the VA Corporate Data Warehouse. Infor-
mation on race was complemented with data obtained from
Medicare through the VA-Medicare data merge project
(19). All blood pressure values available from October 1,
2004, to September 30, 2006, were recorded and grouped by
calendar quarters, and their quarterly averaged values were
used for analyses. Administration of ACEI or ARB wasdefined as the outpatient dispen-
sation by a VA pharmacy of any
agent belonging to these medica-
tion classes, and was assessed
longitudinally in each calendar
quarter for the October 1, 2004 to
September 30, 2009 period. Data
on comorbidities were collected
from the VA Inpatient and Out-
patient Medical SAS Datasets
(20,21) using International Classi-
fication of Diseases-Ninth Revi-
sion diagnostic and procedure
codes and Current Procedural
Terminology codes recorded dur-
ing the October 1, 2004, to Sep-
tember 30, 2006 period. Prevalent
cardiovascular disease was defined
as the presence of diagnostic codes
for coronary artery disease, angina,
or myocardial infarction, or proce-
dure codes for percutaneous coro-
nary interventions or coronary
artery bypass grafting. We calculated the Charlson comorbidity
index using the Deyo modification for administrative
datasets (22).
Laboratory characteristics. Data on laboratory variables
were collected from the October 1, 2004, to September
30, 2009 period by using the National Data Extracts
Laboratory Results file (17). To minimize random vari-
ability, all available laboratory values were grouped by
calendar quarters, and their quarterly averaged values
were used in analyses, except for eGFR values used to
examine progression of CKD, which were examined with
their actual recorded date.
Statistical analyses. Data were characterized using means,
medians, and proportions as appropriate. Skewed variables
were natural log-transformed. Data points were missing for
race (4.5%), blood pressure (5.9%), serum albumin (17.4%),
hemoglobin (11.9%), white blood cell count (12.5%), and
alkaline phosphatase (10.3%). A total of 225,238 patients
(75% of the total study population) had complete data
available for the fully adjusted multivariable analyses. Miss-
ing values were not imputed in the primary analyses but
were substituted by using multiple imputation procedures
(23,24) in sensitivity analyses.
The start of the follow-up period was the date of the
stable eGFR used to establish CKD. Patients were followed
up until death or until the date of the last health-care or
administrative encounter, as documented in the VA Vital
Status Files. The VA Vital Status Files are a registry
containing dates of death or last medical/administrative
encounter from all available sources in the VA system. The
sensitivity and specificity of the Vital Status Files using the
National Death Index as gold standard were shown to
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin-
receptor blocker
CHF  congestive heart
failure
CI  confidence interval
CKD  chronic kidney
disease
CVD  cardiovascular
disease
ESRD  end-stage renal
disease
eGFR  estimated
glomerular filtration rate
UACR  urine
microalbumin-creatinine
ratio
VA  Veterans
Administrationbe 98.3% and 99.8%, respectively (25). The association of
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dependent Cox models, with adjustment for potential con-
founders and clustered by geographic region. The associa-
tion between UACR and progression of CKD was
examined in linear and logistic regression analyses using the
slopes of eGFR versus time as the dependent variable. The
slopes of eGFR were calculated in 277,244 patients who had
at least 3 eGFR values (median 8, Q1 to Q3: 5 to 13) and
a baseline eGFR 15 ml/min/1.73 m2 by ordinary least
squares regression of eGFR versus time in each individual
patient. Progressive CKD was defined as a slope of 4
ml/min/1.73 m2 per year for logistic regression analyses.
Variables were included in multivariable models if they
could be considered confounders (26) on the basis of
theoretical considerations and after examination of baseline
associations with UACR. Associations were examined se-
quentially in models with incremental multivariable adjust-
ments: unadjusted (model 1); age, sex, and race adjusted
(model 2); model 2 plus diabetes, CVD, CHF, and Charl-
son comorbidity index adjusted (model 3); and model 3 plus
blood pressure, administration of ACEI or ARB, eGFR
(except for analyses of slopes), serum albumin, alkaline
phosphatase, hemoglobin, and white blood cell count ad-
justed (model 4). Variables that were measured repeatedly
during follow-up (blood pressure, ACEI/ARB use, and
Baseline Characteristics of Patients Stratified by Level of BaselineTable 1 Baseline Characteristics of Patients Stratified by Leve
Characteristics
<5
(n  72,448)
5 to 9
(n  64,053)
Age, yrs 62.4 11.8 64.6 11.1
Race
White 52,635 (77) 49,988 (82)
Black 12,983 (19) 8,586 (14)
Hispanic 1,041 (1.5) 871 (1.4)
Other 1,658 (2.4) 1,345 (2.2)
Male 69,836 (96) 61,792 (96)
DM 51,363 (71) 50,810 (79)
ASCVD 19,283 (27) 19,728 (31)
CHF 4,405 (6) 4,188 (7)
Comorbidity index 2 (1–3) 2 (1–3)
SBP, mm Hg 132 16 133 16
DBP, mm Hg 75 10 74 11
ACEI/ARB use 19,283 (27) 18,962 (30)
eGFR, ml/min/1.73 m2 78.3 20.3 77.2 19.7
Serum albumin, g/dl 4.1 0.4 4.1 0.4
Total cholesterol, mg/dl 175 40 172 40
Serum calcium, mg/dl 9.3 0.4 9.3 0.4
Serum ALP, U/l 75 31 76 30
Serum bicarbonate, mEq/l 27.7 2.7 27.6 2.7
Blood Hgb, g/dl 14.5 1.5 14.4 1.5
Blood WBC, 1,000/mm3 7.1 3.2 7.3 3.3
UACR, g/mg 3.0 (2.7–4.0) 7.2 (6.0–8.5)
Values are mean  SD, n (% of total), or median (interquartile range). To convert glomerular filtra
ultiply by 10; serum total cholesterol in mg/dl to mmol/l, multiply by 0.02586; serum calcium
ALP  alkaline phosphatase; ACEI  angiotensin-converting enzyme inhibitor; ARB  angiote
BP  diastolic blood pressure; DM  diabetes mellitus; eGFR  estimated glomerular filtration rate; H
BC  white blood cell count.laboratory covariates) were handled as time-dependent
variables in Cox models and as time-averaged values in
regression analyses. Nonlinear associations were examined
by categorizing UACR according to established cutoff
points for male patients (10, 10 to 19, 20 to 199, and
200 g/mg) (14), and by subdividing the 10 g/mg
category into 2 groups (5 and 5 to 9 g/mg) to examine
hether UACR levels below the currently accepted upper
imit of normal (10 g/mg) (14) are still associated with
clinical outcomes, as suggested by some studies (3,6,15).
Analyses were also performed separately in patients catego-
rized according to diabetic status, baseline systolic blood
pressure level (120 mm Hg vs. 120 mm Hg), CVD,
CHF, and eGFR level at baseline (30 ml/min/1.73 m2 vs.
30 ml/min/1.73 m2). To better delineate the role of kidney
unction, we also categorized eGFR according to pre-specified
utoffs of 15 to 29, 30 to 44, 45 to 59, 60 to 89, and 90
l/min/1.73 m2 (27).
Sensitivity analyses were performed by using imputed
values of independent variables. Statistical analyses were
performed using STATA MP Version 11 (Stata Corp.,
College Station, Texas). The study protocol was approved
by the institutional review boards at the Salem VAMC and
the Memphis VAMC.
e Microalbumin-Creatinine Ratioaseline Urine Microalbumin-Creatinine Ratio
Microalbumin/Creatinine, g/mg
10 to 19
(n  55,664)
20 to 199
(n  90,828)
>200
(n  15,882)
66.2 11.2 67.6 11.2 67.4 10.9
44,410 (83) 72,383 (83) 12,339 (80)
6,833 (13) 11,437 (13) 2,266 (15)
827 (1.6) 1,638 (1.9) 320 (2.1)
1,136 (2.1) 1,990 (2.3) 511 (3.3)
53,906 (97) 88,691 (98) 15,723 (98)
46,673 (84) 79,811 (88) 14,593 (91)
19,441 (35) 35,925 (40) 6,888 (43)
4,964 (9) 11,940 (14) 3,288 (21)
2 (1–4) 3 (1–4) 4 (2–5)
134 17 137 18 141 19
74 11 73 11 74 12
17,911 (32) 32,189 (35) 6,230 (39)
74.9 20.9 70.6 20.4 61.5 24.8
4.1 0.4 4.0 0.4 3.80.5
171 41 170 42 172 46
9.3 0.4 9.3 0.5 9.2 0.5
77 32 79 35 86 44
27.6 2.8 27.3 3.0 26.9 3.2
14.3 1.6 14.1 1.7 13.7 1.9
7.4 2.9 7.6 3.5 7.8 3.8
14.0 (11.9–16.7) 44.0 (28.7–78.0) 388.4 (266.3–716.8)
e (GFR) in ml/min/1.73 m2 to ml/s/1.73 m2, multiply by 0.01667; serum albumin in g/dl to g/l,
l to mmol/l, multiply by 0.2495; and hemoglobin in g/dl to g/l, multiply by 10.
eptor blocker; ASCVD  atherosclerotic cardiovascular disease; CHF  congestive heart failure;Urinl of B
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in mg/d
nsin-recgb  hemoglobin; SBP  systolic blood pressure; UACR  urine microalbumin-creatinine ratio;
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Baseline characteristics in patients categorized by their
UACR level are shown in Table 1. Patients with higher
UACR were older, and more likely to be diabetic, to use
ACEI/ARB and to have CVD and CHF, and had a higher
comorbidity index, systolic blood pressure, serum alkaline
phosphatase, and white blood cell count, and lower eGFR,
serum albumin, and hemoglobin.
Mortality. A total of 49,586 patients died (mortality rate
35.3/1,000 patient-years, 95% confidence interval [CI]: 35.0 to
35.7) during a median follow-up of 5 years. Patients with
higher UACR experienced significantly higher mortality rates
in a linearly incremental fashion above a UACR of 10 g/mg
in all models (Fig. 1). When analyzed as a continuous variable,
a 1 natural log-unit higher UACR was associated with hazard
ratios 1.31 (95% CI: 1.28 to 1.34) and 1.11 (95% CI: 1.09 to
1.13) in unadjusted and in fully adjusted models, respectively
(p  0.001 for both).
The association of UACR with mortality was similarly
linear (albeit quantitatively different) in patients with and
without diabetes, CVD, and CHF and in patients with
higher or lower blood pressure levels, but was qualitatively
different in patients with advancedCKD (Fig. 2). UACR levels of
5 to 9, 10 to 19, 20 to 199, and 200 g/mg (compared
to 5 g/mg) were associated with mortality hazard ratios
.05 (95% CI: 0.98 to 1.13), 1.20 (95% CI: 1.12 to 1.29),
.43 (95% CI: 1.33 to 1.54), and 1.57 (95% CI: 1.41 to
Figure 1 Unadjusted and Multivariable Adjusted HR (95% CI) o
Associated With Various Levels of UACR in 298,875 P
In time-dependent Cox models, the groups with urine microalbumin-creatinine ratio
(model 1 [dark red bars]); associations after adjustment for age, sex, and race (m
ease, congestive heart failure, and Charlson comorbidity index (model 3 [yellow-g
enzyme inhibitor/angiotensin-receptor blocker use, estimated glomerular filtration
phosphatase (model 4 [green bars]). *p  0.001; §p  0.05. CI  confidence in.54) in patients with eGFR30 ml/min/1.73 m2; and 0.94
95% CI: 0.80 to 1.10), 0.81 (95% CI: 0.67 to 0.98), 0.96
95% CI: 0.83 to 1.11), and 1.05 (95% CI: 0.88 to 1.25) in
atients with eGFR 30 ml/min/1.73 m2 (Fig. 2). A more
ranular assessment of eGFR categories indicated that
ACR developed a U-shaped association with mortality
elow an eGFR of 45 ml/min/1.73 m2: the adjusted mortality
hazard ratios associated with UACR 10 to 19 compared to5
g/mg in patients with eGFR levels 90, 60 to 89, 45 to 59,
0 to 44, and 15 to 29 ml/min/1.73 m2 were 1.19 (95% CI:
1.08 to 1.31), 1.32 (95% CI: 1.21 to 1.45), 1.11 (95% CI: 1.01
to 1.22), 1.00 (95% CI: 0.86 to 1.15), and 0.81 (95% CI: 0.67
to 0.98) (Online Fig. 1). Furthermore, the magnitude with
which UACR was associated with mortality was highest in
patients with eGFR 60 to 89 ml/min/1.73 m2, and
gradually diminished in patients with eGFR levels 60
ml/min/1.73 m2 (Online Fig. 1). Results of analyses
using imputed values for missing variables yielded similar
results (data not shown).
Progression of CKD. In the overall patient population, a 1
natural log-unit higher UACR was associated with 0.38
ml/min/1.73 m2 per year (95% CI:0.37 to0.39, p 0.001)
and 0.27 ml/min/1.73 m2 per year (95% CI: 0.35 to
0.19, p  0.001) steeper slopes, and with odds ratios (95%
CI) of progressive CKD of 1.18 (95% CI: 1.15 to 1.21, p 
0.001) and 1.12 (95% CI: 1.09 to 1.15, p  0.001) in
unadjusted and in fully adjusted linear and logistic
ause Mortality
nts
R) 5 g/mg served as referent. Models represent unadjusted association
[orange bars]); model 2 variables plus diabetes mellitus, cardiovascular dis-
ars]); and model 3 variables plus systolic blood pressure, angiotensin-converting
erum albumin, blood hemoglobin, white blood cell count, and serum alkaline
HR  hazard ratio.f All-C
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Outcomes Associated With Microalbuminuria April 16, 2013:1626–33regression models, respectively. This association ap-
peared to be linearly incremental at UACR levels 10
g/mg (Fig. 3).
Similar to associations with mortality, the associations of
ACR with progressive CKD were also linearly incremen-
al in all examined subgroups except in patients with
dvanced CKD, in whom there was a U-shaped association
Fig. 4). The U-shaped association between UACR and
rogressive CKD also became apparent in patients with
GFR 45 ml/min/1.73 m2: the adjusted odds ratios of
progressive CKD associated with UACR 10 to 19 com-
pared to 5 g/mg in patients with eGFR levels 90, 60
o 89, 45 to 59, 30 to 44, and 15 to 29 ml/min/1.73 m2
were 1.09 (95% CI: 0.98 to 1.22), 1.19 (95% CI: 1.09 to
1.21), 1.07 (95% CI: 0.98 to 1.16), 0.77 (95% CI: 0.63 to
0.93), and 0.38 (95% CI: 0.26 to 0.56) (Online Fig. 2). Results
of analyses using imputed values for missing variables yielded
Figure 2
Mortality HR (95% CI) Associated with UACR
Categories of 5 to 9, 10 to 19, 20 to 199, and
>200 g/mg, Compared to <5 g/mg in Different
Subgroups of Patients
Results were obtained from Cox models adjusted for age, sex, race, diabetes
mellitus (DM), cardiovascular disease (CVD), congestive heart failure (CHF),
Charlson comorbidity index, systolic blood pressure (BP), angiotensin-convert-
ing enzyme inhibitor/angiotensin-receptor blocker use, estimated glomerular
filtration rate (eGFR), serum albumin, blood hemoglobin, white blood cell count,
and serum alkaline phosphatase. The p values represent significance levels for
interaction terms. ACR  albumin-creatinine ratio; CI  confidence interval;
HR  hazard ratio; UACR  urine microalbumin-creatinine ratio.similar results (data not shown). UDiscussion
We describe associations of UACR with all-cause mortality
and with the slopes of eGFR in a large cohort of U.S.
veterans. Higher UACR showed incremental associations
with both of these outcomes, which were consistent in
patients with and without diabetes, CVD, and CHF and in
patients with lower and higher blood pressure levels. A
markedly different pattern of association was observed in
patients with moderate and advanced CKD. Whereas in
patients with eGFR 60 to 89 ml/min/1.73 m2, UACR levels
of 5 g/mg were associated with the most favorable
utcomes, these associations were U-shaped in patients with
GFR 45, and especially in those with levels 30 ml/
in/1.73 m2 (CKD stages 3B and 4); in the latter groups,
UACR levels 10 to 19 g/mg were associated with a
ignificant increase in adverse outcomes compared to pa-
ients with UACR 10 to 19 g/mg.
Elevated UACR is considered a robust predictor of
adverse clinical outcomes both in the general population
(2–7) and in patients with CKD (8–13). It is less clear,
however, what cutoff should be used to denote a “normal”
UACR. The most commonly used classification considers
UACR 10 g/mg (15 g/mg for females) normal, and
lassifies patients with higher levels as having high-normal
evel, microalbuminuria and macroalbuminuria (14). Desig-
ating an upper limit of normal implies that UACR levels
10 to 15 g/mg are physiologic and are unrelated to
utcomes. This idea has been challenged by studies in the
eneral population showing a decremental association of
ACR levels below this “normal” cutoff with clinical
utcomes (3,6,15), suggesting that any elevation in, and
ndeed, the mere presence of a measurable UACR can in
act be considered pathologic. The determination of a
ormal UACR is important from a public health perspec-
ive, because it could not only define the number of persons
ndentified as being at risk for outcomes or having a disease
uch as CKD, but it would also lead to different therapeutic
argets.
To the best of our knowledge, our study is the first to
escribe in detail the association of low and very low UACR
ith clinical outcomes in patients with different comorbid
onditions. Of these comorbidities, CKD appeared to
epresent an effect-modifier in the association of UACR
ith mortality and with progressive CKD. Explaining the
ifferent associations seen in advanced CKD necessitates
he understanding of what the meaning of a high or a low
ACR is. The most commonly accepted theory is that
ACR represents both a cause and a consequence of
ascular damage (28). Whichever may be the case, it is
ifficult to imagine why patients with CKD who have the
owest UACR levels (and would thus either be at the lowest
isk or have the lowest severity of vascular disease) would
ave higher mortality and more rapid progression of CKD.
more likely explanation of our findings in CKD is that
ACR is also a marker of intraglomerular pressure, and the
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April 16, 2013:1626–33 Outcomes Associated With Microalbuminuriadifferent association patterns seen in some subgroups may
represent their decreased ability to adapt to lower renal
perfusion pressures. Patients with CKD have an inability to
autoregulate end-organ perfusion pressure in the face of
lower blood pressure (29) due to a combination of small
vessel changes (30–32) incurred with the older age and
many of the comorbid conditions present in this group (33).
That could lead to adverse outcomes under conditions of
end-organ ischemia, as has been suggested by numerous
earlier observational studies in end-stage renal disease (33–37)
and in non–dialysis-dependent CKD patients (38,39)
showing a U-shaped association between systolic blood
pressure and mortality. Therefore, it is possible that a low
UACR identifies patients at high risk for ischemic end-
organ damage among those with advanced CKD.
Our findings suggest that when used as a tool for risk
stratification, UACR levels in the lowest range appear to
point toward increased, not decreased, risk of mortality and
progressive CKD in patients with moderate and advanced
CKD. For patients with various other comorbid conditions
and for patients with eGFR levels in the normal range and
those with mild CKD, we confirm findings from studies
involving the general population in that very low UACR
levels can be used to identify patients at the lowest risk for
adverse outcomes. It is less clear how our findings should be
applied toward identifying therapeutic targets, as we cannot
determine from our data what the clinical outcomes would
Figure 3 Unadjusted and Multivariable Adjusted OR (95% CI) o
Associated With Various Levels of UACR in Logistic R
The groups with urine microalbumin-creatinine ratio (UACR) 5 g/mg served as refe
after adjustment for age, sex, and race (model 2 [orange bars]); model 2 variables pl
bidity index (model 3 [yellow-green bars]); and model 3 variables plus systolic blood
albumin, blood hemoglobin, white blood cell count, and serum alkaline phosphatase (
CKD  chronic kidney disease; OR  odds ratio.be if UACR was decreased therapeutically to extremely low rlevels. On the basis of our observational data, it is possible
that in most patients, lowering proteinuria to very low or
undetectable levels could be beneficial. However, in patients
with moderate and advanced CKD, we would consider it
prudent to regard the UACR levels associated with the
lowest risks in observational studies (e.g., 10 to 19 g/mg)
s the optimal therapeutic target worth exploring in clinical
rials.
Our study is notable for its large sample size, which
llowed us to include substantial numbers of patients with
arious comorbidities and with UACR levels spanning a
ide range, and for it being representative of veterans from
he entire geographic United States.
tudy limitations. We examined mostly male patients;
ence, it is unclear whether the same results can be
xtrapolated to female patients. We used data obtained
uring the course of clinical practice; hence, selection bias is
ikely. Our patients’ UACR would have been measured
ased on clinical indications, as suggested by the high
roportion of diabetic patients in our cohort, but the
oncordance of our findings in patients with normal eGFR
ith those of studies examining the general population
upport the validity and generalizability of our results.
onclusions
igher UACR, especially in the macroalbuminemic
gressive CKD
ssion Models
odels represent unadjusted association (model 1 [dark red bars]); associations
etes mellitus, cardiovascular disease, congestive heart failure, and Charlson comor-
re, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker use, serum
4 [green bars]). *p  0.001; #p  0.01; §p  0.05. CI  confidence interval;f Pro
egre
rent. M
us diab
pressu
modelange, is associated with increased mortality and worse
m
i
c
v
s
k
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ence of diabetes mellitus, CVD, CHF, and blood pres-
sure level. In patients with normal kidney function and in
patients with mild decreases in eGFR, the lowest UACR
is also associated with the best outcomes, with the lowest
event rates seen among those with UACR 10 g/mg,
and in some cases, even 5 g/mg. In patients with
oderate and advanced CKD, UACR levels below what
s currently considered normal are associated with worse
linical outcomes. Clinical trials will be needed to test the
alidity of the optimal UACR cutoffs established in our
tudy as therapeutic targets.
Reprint requests and correspondence: Dr. Csaba P. Kovesdy,
Division of Nephrology, Memphis VA Medical Center, 1030
Jefferson Avenue, Memphis, Tennessee 38104. E-mail: csaba.
ovesdy@va.gov.
Figure 4
Odds Ratios (95% CI) of Progressive CKD Associ-
ated With UACR Categories of 5 to 9, 10 to 19,
20 to 199, and >200 g/mg, Compared to
<5 g/mg in Different Subgroups of Patients
Results were obtained from logistic regression models adjusted for age,
sex, race, DM, CVD, CHF, Charlson comorbidity index, systolic BP,
angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker use,
serum albumin, blood hemoglobin, white blood cell count, and serum alkaline
phosphatase. The p values represent significance levels for interaction terms.
CKD  chronic kidney disease; other abbreviations as in Figure 2.REFERENCES
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